|
| Author | Year | Disorder | Population | Intervention | Treatment groups | Dose | Duration | Major finding |
|
| Nemets et al. [94] | 2002 | Major depressive disorder | Israel, 85% female | Add-on to current antidepressant | Ethyl-EPA, placebo (not stated), | 2 g/day | 4 weeks | Improvement in HDRS score over placebo () |
| Peet and Horrobin [95] | 2002 | Major depressive disorder | UK, 84% female | Add-on to current antidepressant | ethyl-EPA 1 g/kg, 2 g/kg,
4 g/kg,
placebo (liquid paraffin), | 1, 2, or 4 g/day | 12 weeks | Improvement in HDRS score over placebo at 1 mg/kg (). No effect at 2 or 4 mg/kg |
| Su et al. [96] | 2003 | Major depressive disorder | Taiwan, 82% female | Add-on to current antidepressat | Fish oil, ,
placebo (olive oil ethyl esters), | 9.6 g/day containing EPA: 4.4 g/day DHA: 2.2 g/day | 8 weeks | Improvement in HDRS score over placebo () |
| Marangell et al. [104] | 2003 | Major depressive disorder | USA, 80% female | Monotherapy | DHA,
placebo (not stated), | 2 g/day | 6 weeks | No effect of treatment on HDRS, CGI or MADRS scores |
| Silvers et al. [106] | 2005 | Depression | New Zealand, 53% female | Add-on to current antidepressant | Fish oil,
placebo (olive oil), | 8 g/day containing EPA: 0.6 g/day DHA: 2.4 g/day | 12 weeks | Improvements in HDRS and BDI scores were greater than, but not significantly different from placebo |
| Nemets et al. [97] | 2006 | Childhood depression | Israel, Gender ratio not stated | Monotherapy | EPA DPA,
placebo (olive or safflower oil), | 1 g/day containing EPA: 400 mg/day DHA: 200 mg/day | 16 weeks | Improvement in CDRS score over placebo () |
| Grenyer et al. [108] | 2007 | Major depressive disorder | Australia, 74% female | Add-on to current antidepressant (74% of subjects) or Monotherapy | Fish oil,
placebo (olive oil), | 8 g/day containing EPA: 0.6 g/day DHA: 2.2 g/day | 16 weeks | No effect of treatment on BDI score |
| Su et al. [98] | 2008 | Major depression during pregnancy | Taiwan, 100% female | Monotherapy | EPADHA, placebo (olive oil ethyl esters), | EPA: 2.2 g/day DHA: 1.2 g/day | 8 weeks | Improvement in HDRS over placebo () and higher response rate () |
| da Silva et al. [101] | 2008 | Depression in Parkinson's disease | Brazil, Gender ratio not stated | Monotherapy or add-on to current antidepressant | Fish oil only, , Fish oil antidepressant, , placebo (mineral oil), , , | EPA: 720 mg/day DHA: 480 mg/day | 12 weeks | Improvement in MADRS score compared to placebo or placebo antidepressant () |
| Rogers et al. [105] | 2008 | Mild to moderate depression | UK, Gender ratio not stated | Monotherapy | EPA DHA, , placebo (olive oil with 7.5 mg mixed tocopherols), | EPA: 630 mg/day, DHA: 850 mg/day | 12 weeks | No effect of treatment on DASS or BDI scores |
| Lucas et al. [99] | 2009 | Middle-aged women with psycholo gical distress and depressive symptoms | Canada, 100% female | Monotherapy | Ethyl-EPA, placebo (sunflower oil), | 1.5 g/day containing EPA: 1.05 g/day DHA: 0.15 g/day | 8 weeks | Improvement in HDRS score was greater than placebo only for subjects not meeting criteria for major depression () |
| Mischoulon et al. [107] | 2009 | Major depressive disorder | USA, 65% female | Monotherapy | Ethyl-EPA, placebo (paraffin oil with 0.2% -tocopherol), | 1 g/day | 8 weeks | Improvement in HDRS score was greater than, but not significantly different from placebo |
| Rondanelli et al. [100] | 2010 | Elderly women with depression | Italy, 100% female | Monotherapy | EPA DHA, , placebo (paraffin oil), | EPA: 1.67 g/day, DHA: 0.83 g/day | 8 weeks | Improvement in GDS score over placebo (). |
| Bot et al. [109] | 2010 | Major depression in diabetes mellitus | The Netherlands, 52% female | Add-on to current antidepressant | Ethyl-EPA, placebo (rapeseed oil with medium chain triglycerides), | 1 g/day | 12 weeks | No effect of treatment on MADRS score |
|
